BioCentury | Apr 7, 2021
Product Development

As Scholar Rock readies for SMA Phase III, investors shed shares amid varied durability data

...Senior Editor Scholar Rock is moving apitegromab (SRK-015) into Phase III this year, but the myostatin...
...October, Scholar Rock’s share price more than doubled.TARGETSMSTN (GDF8) – Myostatin Lauren Martz Apitegromab (SRK-015) Scholar Rock Holding Corp. Myostatin (MSTN) (GDF8) SMA...
BioCentury | Nov 24, 2020
Product Development

Nov. 24 Quick Takes: Elevian raises $15M; plus AZ-Ionis, Genmab, Moderna and Novartis

Anti-aging play Elevian raises $15M equity roundElevian Inc. raised $15 million in an equity financing led by Prime Movers Lab. Also participating were Bold Capital Partners, For Good Ventures, Kizoo Ventures, Lauder Partners, Longevity Fund,...
BioCentury | Nov 20, 2020
Translation in Brief

Long-term gene therapy study in dogs with hemophilia A; plus a comparison of HBV vaccine adjuvants and mAb that alleviates chemotherapy side effects

Long-term study of AAV gene therapy in dogs finds genome integration, clonal expansionA team led by University of Pennsylvania scientists showed in Nature Biotechnology that adeno-associated viral (AAV8 or AAV9) gene therapy corrected factor VIII...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...
BioCentury | Oct 27, 2020
Product Development

SMA data validate growth factor-targeting platform for Scholar Rock as stock price doubles

...breathes new life into theory that blocking myostatin... life into the theory that blocking myostatin... by binding the latent form of myostatin...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jul 16, 2020
Emerging Company Profile

Fountain Therapeutics: an AI-based platform to reverse cellular aging

Fountain is using an unbiased data-driven approach to identify compounds that reverse the biological process of aging, and in contrast to the traditional disease hypothesis-driven approach, the company is agnostic to indication. “Eighty percent of...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...Acceleron Pharma Inc. (NASDAQ:XLRN) is discontinuing development of ACE-083 after the ligand trap inhibitor of MSTN... Targets HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 MSTN (GDF8) - Myostatin...
BioCentury | Mar 11, 2020
Product Development

Novo’s year of obesity

Novo Nordisk is set to deliver six clinical readouts in obesity in 2020. If successful, they could deliver Novo an opportunity to dramatically expand a mostly untapped market that could become a major future growth...
BioCentury | Dec 23, 2019
Company News

Roche’s ex-U.S. deal for Sarepta DMD programs could extend beyond micro-dystrophin gene therapy

...hemophilia, lysosomal storage disorders and neurodegenerative diseases. In November, Roche discontinued development of RG6206, its anti-myostatin...
...Co. (NYSE:BMY) $170 million up front in 2017 to gain that therapy’s rights (see “Second Myostatin...
Items per page:
1 - 10 of 147